The latest price target for Immix Biopharma (NASDAQ:IMMX) was reported by HC Wainwright & Co. on October 3, 2024. The analyst firm set a price target for $7.00 expecting IMMX to rise to within 12 months (a possible 233.33% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Immix Biopharma (NASDAQ:IMMX) was provided by HC Wainwright & Co., and Immix Biopharma reiterated their buy rating.

There is no last upgrade for Immix Biopharma

There is no last downgrade for Immix Biopharma.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Immix Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Immix Biopharma was filed on October 3, 2024 so you should expect the next rating to be made available sometime around October 3, 2025.

While ratings are subjective and will change, the latest Immix Biopharma (IMMX) rating was a reiterated with a price target of $7.00 to $7.00. The current price Immix Biopharma (IMMX) is trading at is $2.10, which is out of the analyst’s predicted range.